Single Center Experience with the Heartmate 3 Continuous-Flow Ventricular Assist Device in Pediatric Patients

Trezzi, Matteo; Brancaccio, Gianluca; Filippelli, Sergio; Galletti, Lorenzo; Adorisio, Rachele; Iacobelli, Roberta; Giorni, Chiara; Selvaggio, D.; Amodeo, Antonio

doi:10.1016/j.healun.2021.01.1235

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 The absence of pump thrombosis, stroke, and driveline infection was also reported in a single-center cohort of pediatric patients with a median follow-up of 138 days post implantation. 8 Regarding length of hospitalization after LVAD implantation, in our case the patient spent 4 days in the intensive care unit and was discharged home after 16 days, with comparable results to those obtained in the ACTION cohort in which the median hospital length of stay to the time of discharge or heart transplantation after HM3 implantation was 29.5 (range 2−170) days, while the median number of days spent in intensive care unit was 14 (range 2−48) days. 5…”

Section: Case Presentationmentioning

confidence: 99%

See 1 more Smart Citation

First Pediatric HeartMate 3 Ventricular Assist Device Implantation in Romania – a Case Report

Muntean,

Iurian,

Nistor

et al. 2024

Journal of Cardiovascular Emergencies

View full text Add to dashboard Cite

The use of ventricular assist devices as bridge-to-transplantation therapy has a critical role in the management of end-stage heart failure in pediatric patients without available compatible organ donors. The HeartMate 3 is an intracorporeal centrifugal flow pump with a fully magnetically levitated motor currently approved for the management of advanced refractory left ventricular failure in pediatric patients, with positive early outcomes. We report the case of a 17-year-old adolescent girl with end-stage heart failure secondary to dilated cardiomyopathy of idiopathic etiology, with multiple failed attempts of weaning from inotropic support (PEDIMACS 3 profile), who successfully received a HeartMate 3 left ventricular assist device as bridge-to-transplantation therapy with no significant adverse events during the early follow-up period. This paper presents the first case of pediatric ventricular assist device implantation in Romania.

show abstract

Section: Case Presentationmentioning

confidence: 99%

“…[3][4][5][6] The HM3 is currently approved by the US Food and Drug Administration for the management of advanced refractory left ventricular failure in pediatric patients with encouraging reported early outcomes and a low incidence of adverse events and mortality. 5,7,8…”

Section: Introductionmentioning

confidence: 99%

First Pediatric HeartMate 3 Ventricular Assist Device Implantation in Romania – a Case Report

Muntean,

Iurian,

Nistor

et al. 2024

Journal of Cardiovascular Emergencies

View full text Add to dashboard Cite

show abstract

“…In one cohort, HM3 was successfully implanted in five children with a median age of 14.5 years (9-16.5 years), median weight of 48 kg (40-75.0 kg), and a median BSA of 1.43 m 2 (1.36-1.92 m 2 ). 17 Moreover, recent data from the ACTION (Advanced Cardiac Therapies Improving Outcomes Network) registry between December 2017 and September 2019 reported the outcomes of HM3 implantation in 35 young patients. 18 In the ACTION registry, 28 (80%) were aged <18 years with a median age of 15.7 years (8.8-47.3 years), had a median weight of 65.7 kg (19.1-114.1 kg) and a median BSA of 1.74 m 2 (0.78-2.36 m 2 ), with the majority of recipients (63%) having dilated cardiomyopathy; the survival rate was 97% out to the median of 78 days of follow-up.…”

Section: Impact On Paediatric Patientsmentioning

confidence: 99%

“…In one cohort, HM3 was successfully implanted in five children with a median age of 14.5 years (9–16.5 years), median weight of 48 kg (40–75.0 kg), and a median BSA of 1.43 m 2 (1.36–1.92 m 2 ). [ 17 ]…”

Section: Impact On Paediatric Patientsmentioning

confidence: 99%

Ventricular Assist Devices: Challenges of the One-device Era

et al. 2022

View full text Add to dashboard Cite

Heart failure (HF) is linked to to high mortality rates and recurrent hospitalisations despite medical and device-based achievements. The use of left ventricular assist devices (LVADs) has improved survival among patients with advanced HF. Significant progress has been achieved with the new generation of continuous-flow devices, particularly with the fully magnetically levitated HeartMate 3. In June 2021, Medtronic announced the abrupt withdrawal of the HeartWare device from the market. This decision has introduced a new era in which the field of mechanical support for advanced HF patients is dominated by a single device – the HeartMate 3. The direct clinical and economic consequences of this change will necessitate new surgical considerations. Because of the expected need for HeartWare device replacement in small patients, new surgical techniques and device adaptation will be needed. The new single-device era will hopefully encourage scientists and engineers to create innovations in the advanced HF arena. Special considerations should be taken during the COVID-19 pandemic when treating patients with LVADs.

show abstract

An Up-to-Date Literature Review on Ventricular Assist Devices Experience in Pediatric Hearts

Moisă

Burlacu

Brinza

et al. 2022

Life

View full text Add to dashboard Cite

Ventricular assist devices (VAD) have gained popularity in the pediatric population during recent years, as more and more children require a heart transplant due to improved palliation methods, allowing congenital heart defect patients and children with cardiomyopathies to live longer. Eventually, these children may require heart transplantation, and ventricular assist devices provide a bridge to transplantation in these cases. The FDA has so far approved two types of device: pulsatile and continuous flow (non-pulsatile), which can be axial and centrifugal. Potential eligible studies were searched in three databases: Medline, Embase, and ScienceDirect. Our endeavor retrieved 16 eligible studies focusing on five ventricular assist devices in children. We critically reviewed ventricular assist devices approved for pediatric use in terms of implant indication, main adverse effects, and outcomes. The main adverse effects associated with these devices have been noted to be thromboembolism, infection, bleeding, and hemolysis. However, utilizing left VAD early on, before end-organ dysfunction and deterioration of heart function, may give the patient enough time to recuperate before considering a more long-term solution for ventricular support.

show abstract

Single Center Experience with the Heartmate 3 Continuous-Flow Ventricular Assist Device in Pediatric Patients

Cited by 3 publications

References 0 publications

First Pediatric HeartMate 3 Ventricular Assist Device Implantation in Romania – a Case Report

First Pediatric HeartMate 3 Ventricular Assist Device Implantation in Romania – a Case Report

Ventricular Assist Devices: Challenges of the One-device Era

An Up-to-Date Literature Review on Ventricular Assist Devices Experience in Pediatric Hearts

Contact Info

Product

Resources

About